Symvivo Corporation is a clinical-stage biotechnology company that develops DNA vaccines for genetic and life-threatening diseases.
Symvivo Corporation has raised $650K in total funding. The most recent round was Grant. The last funding was announced in May 2022.
Symvivo Corporation's investors include Pacific Economic Development Canada.
Symvivo Corporation is headquartered in Burnaby, Canada.
Symvivo Corporation is a clinical-stage biotechnology company that develops DNA vaccines for genetic and life-threatening diseases.
Symvivo Corporation is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Symvivo Corporation — Funding & Investors." VCBacked, May 31, 2022, https://www.vcbacked.co/company/symvivo-corporation. Accessed September 30, 2026.
VCBacked. (2022). Symvivo Corporation — Funding & Investors. Retrieved September 30, 2026, from https://www.vcbacked.co/company/symvivo-corporation
{{cite web |title=Symvivo Corporation — Funding & Investors |url=https://www.vcbacked.co/company/symvivo-corporation |website=VCBacked |access-date=September 30, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated